Correction: Impact of Timing for Adjuvant Chemotherapy Following Cytoreductive Surgery

Overview

This correction addresses the placement of figures and text in a study analyzing the timing of adjuvant chemotherapy after cytoreductive surgery in epithelial ovarian cancer. The study included 145 patients and aimed to evaluate the impact of chemotherapy timing on survival outcomes.

Background

The timing of adjuvant chemotherapy following cytoreductive surgery is a critical factor in the management of epithelial ovarian cancer. Delays in initiating chemotherapy may adversely affect survival outcomes.

Data Highlights

No numerical or trial data is presented in the correction article.

Key Findings

• The correction clarifies the placement of Figure 1 in the Results section.
• The patient selection process was illustrated in a Flow Diagram that was omitted in the original publication.
• The study cohort consisted of 145 patients treated between January 2016 and December 2021.
• Eligible patients had histologically confirmed epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
• Exclusion criteria included secondary cytoreductive surgery for recurrent disease and non-epithelial ovarian tumors.

Clinical Implications

Clinicians should be aware of the importance of timely initiation of adjuvant chemotherapy following cytoreductive surgery. This correction emphasizes the need for accurate representation of study data to inform clinical decisions.

Conclusion

The correction serves to clarify the methodology and findings of the original study.

Related Resources & Content

1. Jamdade K et al., Frontiers in Oncology, 2026 -- Impact of Timing for Adjuvant Chemotherapy Following Cytoreductive Surgery
2. The ASCO Post — Improved Survival With Shorter Delays Between Diagnosis and Surgery and Before Initiating Adjuvant Chemotherapy
3. The ASCO Post — Secondary Surgical Cytoreduction Plus Chemotherapy vs Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer
4. the asco post — Trends in Use of Primary Cytoreductive Surgery and Neoadjuvant Chemotherapy in Advanced-Stage Ovarian Cancer
5. the asco post — Mortality in Advanced-Stage Ovarian Cancer—Effect of Neoadjuvant Chemotherapy and Cytoreductive Surgery Case Volume
6. ESMO Clinical Practice Guideline Express Update on the management of epithelial ovarian cancer
7. ASCO Updates Guidelines on Neoadjuvant Chemotherapy in Advanced Ovarian Cancer
8. Timing matters: Surgery-to-chemotherapy interval and outcomes in ovarian cancer - ScienceDirect